These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38983711)

  • 1. Long-acting HIV Treatments: Study Design, Logistics, and Access.
    Murdock NA; Alajaji NE; Schaefer R; Boone CA; Campo RE; Dore GJ; Gandhi M; Gorospe JR; Gulick RM; Hodder SL; Liu J; Rhee MS; Rooney JF; Vannappagari V; Wilkin T; Miller V
    Open Forum Infect Dis; 2024 Jul; 11(7):ofae337. PubMed ID: 38983711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.
    Jenkins SY; Resar D; Panos Z; Staple A; Watkins M; Ripin D; Amole C
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26101. PubMed ID: 37439082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
    Moreno S; Rivero A; Ventayol P; Falcó V; Torralba M; Schroeder M; Neches V; Vallejo-Aparicio LA; Mackenzie I; Turner M; Harrison C
    Infect Dis Ther; 2023 Aug; 12(8):2039-2055. PubMed ID: 37452174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study.
    Mukherjee J; Rawat S; Ul Hadi S; Aggarwal P; Chakrapani V; Rath P; Manchi P; Aylur S; Malhotra S; Keane M; Gangaramany A
    JMIR Res Protoc; 2024 Feb; 13():e47700. PubMed ID: 38324364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgender Women's Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs).
    Rael CT; Martinez M; Giguere R; Bockting W; MacCrate C; Mellman W; Valente P; Greene GJ; Sherman SG; Footer KHA; D'Aquila RT; Carballo-Diéguez A; Hope TJ
    AIDS Behav; 2020 May; 24(5):1452-1462. PubMed ID: 31654172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment.
    Grimsrud A; Wilkinson L; Delany-Moretlwe S; Ehrenkranz P; Green K; Murenga M; Ngure K; Otwoma NJ; Phanuphak N; Vandevelde W; Vitoria M; Bygrave H
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26095. PubMed ID: 37439076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Acting Injectable Antiretrovirals for HIV Treatment: A Multi-Site Qualitative Study of Clinic-Level Barriers to Implementation in the United States.
    McCrimmon T; Collins LF; Perez-Brumer A; Bazzi AR; Shaffer VA; Kerrigan D; Alcaide ML; Philbin MM
    AIDS Patient Care STDS; 2024 Feb; 38(2):61-69. PubMed ID: 38381949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol: the ILANA study - exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK - a qualitative multiphase longitudinal study design.
    Farooq HZ; Apea V; Kasadha B; Ullah S; Hilton-Smith G; Haley A; Scherzer J; Hand J; Paparini S; Phillips R; Orkin CM
    BMJ Open; 2023 Jul; 13(7):e070666. PubMed ID: 37423623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing Implementation Strategies for the Inclusion of Lesbian, Gay, Bisexual, Transgender, Intersex, Queer, and Allied and Key Populations' Content in Undergraduate Nursing Curricula in KwaZulu-Natal, South Africa: Protocol for a Multimethods Research Project.
    Nxumalo CT; Luvuno Z; Chiya WH; Ngcobo SJ; Naidoo D; Zamudio-Haas S; Harris O
    JMIR Res Protoc; 2024 May; 13():e52250. PubMed ID: 38598816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.
    Isfordink CJ; Boyd A; Sacks-Davis R; van Santen DK; Smit C; Martinello M; Stoove M; Berenguer J; Wittkop L; Klein MB; Rauch A; Salmon D; Lacombe K; Stewart A; Schinkel J; Doyle JS; Hellard M; van der Valk M; Matthews GV;
    Lancet Public Health; 2023 Apr; 8(4):e294-e304. PubMed ID: 36965984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient Education and Decision Support for Long-Acting Injectable HIV Antiretroviral Therapy: Protocol for Tool Development and Pilot Testing with Ryan White HIV/AIDS Program Medical Case Management Programs in New York.
    Irvine MK; Zimba R; Avoundjian T; Peterson M; Emmert C; Kulkarni SG; Philbin MM; Kelvin EA; Nash D
    JMIR Res Protoc; 2024 Mar; 13():e56892. PubMed ID: 38536227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV/AIDS: a minority health issue.
    Cargill VA; Stone VE
    Med Clin North Am; 2005 Jul; 89(4):895-912. PubMed ID: 15925655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What does the scale-up of long-acting HIV pre-exposure prophylaxis mean for the global hepatitis B epidemic?
    Mohareb AM; Kouamé MG; Nouaman M; Kim AY; Larmarange J; Neilan AM; Lacombe K; Freedberg KA; Boyd A; Coffie P; Hyle EP
    J Int AIDS Soc; 2024 Mar; 27(3):e26218. PubMed ID: 38444112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Australian guidelines for the treatment of alcohol problems: an overview of recommendations.
    Haber PS; Riordan BC; Winter DT; Barrett L; Saunders J; Hides L; Gullo M; Manning V; Day CA; Bonomo Y; Burns L; Assan R; Curry K; Mooney-Somers J; Demirkol A; Monds L; McDonough M; Baillie AJ; Clark P; Ritter A; Quinn C; Cunningham J; Lintzeris N; Rombouts S; Savic M; Norman A; Reid S; Hutchinson D; Zheng C; Iese Y; Black N; Draper B; Ridley N; Gowing L; Stapinski L; Taye B; Lancaster K; Stjepanović D; Kay-Lambkin F; Jamshidi N; Lubman D; Pastor A; White N; Wilson S; Jaworski AL; Memedovic S; Logge W; Mills K; Seear K; Freeburn B; Lea T; Withall A; Marel C; Boffa J; Roxburgh A; Purcell-Khodr G; Doyle M; Conigrave K; Teesson M; Butler K; Connor J; Morley KC
    Med J Aust; 2021 Oct; 215 Suppl 7():S3-S32. PubMed ID: 34601742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.
    Mantsios A; Murray M; Karver TS; Davis W; Galai N; Kumar P; Swindells S; Bredeek UF; García RR; Antela A; Gomis SC; Bernáldez MP; Czarnogorski M; Hudson K; Walters N; Kerrigan D
    BMC Health Serv Res; 2021 Mar; 21(1):255. PubMed ID: 33743684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of the epidemiological conditions of HIV among key populations in Africa.
    Jin H; Restar A; Beyrer C
    J Int AIDS Soc; 2021 Jul; 24 Suppl 3(Suppl 3):e25716. PubMed ID: 34190412
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.